Overall, increased apoptotic response and decreased MYC expression highlight AZD5153 and pazopanib as an effective drug combination in mitigating DDLPS progression in vivo, with significant tumor suppressive activity compared to either drug alone. This evidence concerns the gene MYC and neoplasm.